Spyre Therapeutics Inc
spyre.comSpyre Therapeutics Inc (NASDAQ: SYRE) is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for immune-mediated diseases. The company generates no product revenue and funds operations through capital markets activity, as all pipeline candidates remain in clinical development as of the FY2025 10-K filed February 19, 2026. Spyre's pipeline targets inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and other rheumatic diseases, with lead candidates SPY001, SPY002, SPY072, and SPY003 in Phase 1 trials. The company was formed through the acquisition of assets from the original Spyre Therapeutics Inc. (Pre-Merger Spyre), referred to internally as the Asset Acquisition. Shares trade on the Nasdaq Global Select Market. As of June 30, 2025, the aggregate market value of common equity held by non-affiliates was approximately based on a closing price of $14.97 per share.
Products & Services
Pipeline antibody therapeutics: SPY001, SPY002, SPY072, and SPY003, all in Phase 1 clinical trials as of the FY2025 filing. Target indications include IBD, RA, PsA, axSpA, and other immune-mediated and rheumatic diseases.
Revenue Model
No product revenue. Pre-commercial stage; operations are funded through equity and capital markets financing. No partnerships or royalty agreements are disclosed in the excerpts.
Customers & Markets
No commercial customers. Target end markets are patients with inflammatory bowel disease, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and related rheumatic diseases.
Geographic Exposure
Incorporated and headquartered in the United States; listed on Nasdaq Global Select Market. No geographic revenue breakdown disclosed in the excerpts.
Financial Snapshot
Loading...
